Author

Nervin Lawendy 1

1 Pfizer Inc,Collegeville,United States

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Bruce E. Sands, Walter Reinisch, Julian Panés, Paulo Gustavo Kotze, Donna T Judd, Rajiv Mundayat, Nervin Lawendy

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi, Christina Ha, Michael Chiorean, Nervin Lawendy, Rajiv Mundayat, Leonardo Salese, John C. Woolcott, Chinyu Su, Iris Dotan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, Geert R. D'Haens, William J. Sandborn, Julian Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, nicole kulisek, Irene Modesto, Siew C. Ng, Joana Torres

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés, Jean-Frederic Colombel, Severine Vermeire, Marla C. Dubinsky, Ala I. Sharara, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Edward V. Loftus Jr.

EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE

Susan B. Connelly, Nervin Lawendy, Jerome Paulissen, Krisztina Barbara Gecse, Scott Lee, Flavio Steinwurz, Jessica Allegretti

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Kevin L. Winthrop, Gil Y. Melmed, Severine Vermeire, Nervin Lawendy, Rajiv Mundayat, nicole kulisek, Chinyu Su

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Kevin L. Winthrop, Severine Vermeire, Julian Panés, Gil Y. Melmed, nicole kulisek, Rajiv Mundayat, Nervin Lawendy, Chinyu Su

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, William J. Sandborn, Sean Gardiner, Rajiv Mundayat, Irene Modesto, Jerome Paulissen, Severine Vermeire, Paulo Kotze, Chinyu Su, Nervin Lawendy, nicole kulisek, Geert D’Haens, Joana Torres

Item 1 - 10 / 32
1
2 3 4